2026-10-12T15:47:19Z https://api.figshare.com/v2/oai

oai:figshare.com:article/33994518 2026-09-25T10:44:53Z category_7 portal_147 item_type_3 month_year_09_2026

Supplemental Material for: Atezolizumab plus Bevacizumab Versus Durvalumab plus Tremelimumab in Unresectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Multicenter Retrospective Study figshare admin karger (2628495) Yasuto Takeuchi (19740046) Shigeo Shimose (19740043) Joji Tani (8382321) Takanori Ito (74201) Takanori Matsuura (2403088) Yuichi Honma (3185235) Norikazu Tanabe (741996) Tetsu Tomonari (4062613) Nobuhito Taniki (549431) Ryu Sasaki (754133) Takeshi Hatanaka (11603062) Satoru Kakizaki (65174) Kyo Sasaki (19740055) Naoki Yoshioka (1934140) Takafumi Yamamoto (1466065) Takehito Naito (19740049) Mamiko Takeuchi (19740052) Tetsuya Yasunaka (591273) Tomotake Shirono (19740058) Takaya Suzuki (3274881) Rintaro Kobayashi (25109358) Atsushi Naganuma (449391) Sohji Nishina (16825617) Hisamitsu Miyaaki (3825778) Nobuhiro Nakamoto (13920249) Tetsuji Takayama (4060351) Taro Takami (742001) Masaru Harada (2954517) Yuzo Kodama (5718695) Hiroki Kawashima (5290955) Hideki Kobara (400974) Takumi Kawaguchi (329250) Motoyuki Otsuka (205227) Hepatology InVestigator Experts in Japan (HIVE-J) Study Group (25109362) Medicine Medicine <p dir="ltr">Introduction: The optimal ICI-based systemic treatment for unresectable hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT), particularly main portal vein invasion, remains unclear. We compared atezolizumab plus bevacizumab (ATZ/BEV) and durvalumab plus tremelimumab (DUR/TRE) according to PVTT extent. Methods: This multicenter retrospective study included 1,015 patients treated with ATZ/BEV and 186 treated with DUR/TRE. Treatment response, progression-free survival (PFS), overall survival (OS), and safety were compared between groups. Subgroup analyses were performed according to PVTT extent. Results: In the overall cohort, the objective response rate was comparable between the ATZ/BEV and DUR/TRE groups (31.0% vs. 31.7%, P = 0.86), whereas the disease control rate was significantly higher in the ATZ/BEV (78.4% vs. 62.4%, P < 0.01). Median PFS was significantly longer with ATZ/BEV than with DUR/TRE (6.9 vs. 5.3 months, P = 0.049), whereas median OS was comparable between groups (24.9 vs. 31.0 months, P = 0.72). In subgroup analyses stratified by PVTT extent, PFS and OS were generally comparable in patients with Vp1–Vp3 disease. However, among patients with Vp4 disease, median OS was significantly longer with ATZ/BEV than with DUR/TRE (16.6 vs. 6.1 months; HR, 3.60; 95% CI, 1.33–9.74; P < 0.01). The OS difference in Vp4 disease was attenuated and no longer significant in an 8-week landmark analysis. Conclusion: ATZ/BEV was associated with a longer PFS than DUR/TRE in the overall cohort. In patients with Vp4 PVTT, ATZ/BEV may be associated with favorable survival outcomes; however, these findings should be considered hypothesis-generating and require validation.</p> 2026-09-25T10:44:53Z Dataset Dataset 10.6084/m9.figshare.33994518.v1 https://figshare.com/articles/dataset/Supplemental_Material_for_Atezolizumab_plus_Bevacizumab_Versus_Durvalumab_plus_Tremelimumab_in_Unresectable_Hepatocellular_Carcinoma_with_Portal_Vein_Tumor_Thrombus_A_Multicenter_Retrospective_Study/33994518 CC BY 4.0